HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.

Abstract
Ninety percent of glucose filtered by the glomerulus is reabsorbed by a sodium-glucose cotransporter 2 (SGLT2), which is mainly expressed on S1 and S2 segment of renal proximal tubules. Since SGLT-2-mediated glucose reabsorption is increased under diabetic conditions, selective inhibition of SGLT2 is a potential therapeutic target for the treatment of diabetes. We have recently shown that an inhibitor of SGLT2 has anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing advanced glycation end products formation and oxidative stress generation in the kidney. However, the direct effects of SGLT2 inhibitor on tubular cell damage remain unclear. In this study, we investigated the effects of tofogliflozin, a highly selective inhibitor of SGLT2 on oxidative stress generation, inflammatory and proapoptotic reactions in cultured human proximal tubular cells exposed to high glucose. Tofogliflozin dose-dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were suppressed by the treatment of tofogliflozin or an antioxidant N-acetylcysteine (NAC). Monocyte chemoattractant protein-1 (MCP-1) gene expression and apoptotic cell death were induced by 4 h- and 8 day-exposure to high glucose, respectively, both of which were also blocked by tofogliflozin or NAC. The present study suggests that SGLT2-mediated glucose entry into tubular cells could stimulate oxidative stress and evoke inflammatory and proapoptotic reactions in this cell type. Blockade of glucose reabsorption in tubular cells by SGLT2 inhibitor might exert beneficial effects on tubulointerstitial damage in diabetic nephropathy.
AuthorsY Ishibashi, T Matsui, S Yamagishi
JournalHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (Horm Metab Res) Vol. 48 Issue 3 Pg. 191-5 (Mar 2016) ISSN: 1439-4286 [Electronic] Germany
PMID26158396 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© Georg Thieme Verlag KG Stuttgart · New York.
Chemical References
  • Benzhydryl Compounds
  • Chemokine CCL2
  • Glucosides
  • RNA, Messenger
  • Reactive Oxygen Species
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Glucose
  • 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol
Topics
  • Apoptosis (drug effects, genetics)
  • Benzhydryl Compounds (pharmacology, therapeutic use)
  • Cell Line
  • Chemokine CCL2 (genetics, metabolism)
  • Gene Expression Regulation (drug effects)
  • Glucose (pharmacology)
  • Glucosides (pharmacology, therapeutic use)
  • Humans
  • Inflammation (drug therapy, pathology)
  • Kidney Tubules, Proximal (drug effects, pathology)
  • Oxidative Stress (drug effects, genetics)
  • RNA, Messenger (genetics, metabolism)
  • Reactive Oxygen Species (metabolism)
  • Sodium-Glucose Transporter 2 (metabolism)
  • Sodium-Glucose Transporter 2 Inhibitors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: